samedan logo
 
 
spacer
home > ebr > winter 2003 > drug discovery in the post-genomic era
PUBLICATIONS
European BioPharmaceutical Review

Drug Discovery in the Post-Genomic Era

2003 marked the completion of the human genome project and we now find ourselves in a post-genomic era, trying to understand and utilise a previously unimaginable amount of biological information. Scientists have the daunting task of finding new ways to use the human genome sequence for the benefit of humanity - to develop new drugs and to find better ways to combat disease.

Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Steve Lombardi, Vice President of Corporate Development at Affymetrix, Inc

Steve Lombardi is Vice President of Corporate Development at Affymetrix, Inc. He has made significant progress in moving early-stage, advanced technology out to customers. Prior to joining Affymetrix, Steve was Senior Vice President of Applications and Products for Applied Biosystems, managing strategic marketing and applications R&D. He earned his BA in Biology from Merrimack College.

spacer
Steve Lombardi
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Clinical Trials in CNS

25-26 November 2008, Copthorne Tara Hotel, London, UK

SMi present their 7th annual conference… Clinical Trials in CNS 25th to 26th November 2008, Copthorne Tara Hotel, London, UK
More info >>

 
News and Press Releases

Azopharma Product Development Group, Inc

HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement